Loading
Newly diagnosed transplant-eligible myeloma: 4 induction cycles, ASCT, 2 consolidation cycles, then D-R maintenance
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Daratumumab Monoclonal antibody (anti-CD38) | 1,800 mg weekly cycles 1-2, every 2 weeks cycles 3-6, every 4 weeks thereafter | SC | D1, 8, 15, 22 | |
Bortezomib Proteasome inhibitor | 1.3 mg/m² | SC | D1, 4, 8, 11 | |
Lenalidomide Immunomodulatory drug (cereblon E3 ligase modulator) | 25 mg once daily | Oral | D1-21 | |
Dexamethasone | 40 mg | Oral | D1, 2, 3, 4, 9, 10, 11, 12 |
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.